{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:06:28Z","timestamp":1792195588043,"version":"4.4.0"},"reference-count":25,"publisher":"American Chemical Society (ACS)","issue":"21","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_13065"],"award-info":[{"award-number":["MC_PC_13065"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Resistance to imatinib, a first-line BCR-ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia, is frequently mediated by drug efflux through P-glycoprotein (P-gp) overexpression. We report the design, synthesis, and evaluation of eight novel imatinib derivatives modified at the piperazine terminus with efflux resistance breaker (ERB) fragments to reduce P-gp-mediated efflux. In silico docking against cryo-EM P-gp structures predicted increased hydrophobic interactions and enhanced occupancy at the access tunnel, indicative of efflux inhibition. Compound 8 showed potency comparable to imatinib in BCR-ABL1+ K562 cells and a lower LC50 fold change in resistant K562\/DOX cells, suggesting reduced efflux susceptibility. Accumulation assays confirmed the improved intracellular retention of compound 8. Compound 9 displayed increased potency in resistant cells, correlating with higher intracellular levels despite modest kinase inhibition. Verapamil assays confirmed reduced efflux liability for compounds 8 and 13. Compound 8 also showed a positive therapeutic index. These findings support rational design to mitigate efflux-mediated resistance.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c01596","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T13:29:28Z","timestamp":1761398968000},"page":"22619-22632","source":"Crossref","is-referenced-by-count":2,"title":["Design, Synthesis,\nand Biological Evaluation of Efflux-Resistant\nImatinib Derivatives"],"prefix":"10.1021","volume":"68","author":[{"given":"Madiha M.","family":"Chowdhury","sequence":"first","affiliation":[{"name":"King\u2019s College London , , ,","place":["London, U.K., SE1 9NH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priantha","family":"Pretheshan","sequence":"additional","affiliation":[{"name":"King\u2019s College London , , ,","place":["London, U.K., SE1 9NH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasima S.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"King\u2019s College London , , ,","place":["London, U.K., SE1 9NH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Andriollo","sequence":"additional","affiliation":[{"name":"King\u2019s College London , , ,","place":["London, U.K., SE1 9NH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2350-6384","authenticated-orcid":true,"given":"Ajit J.","family":"Shah","sequence":"additional","affiliation":[{"name":"University of Middlesex , , The Burroughs, Hendon , ,","place":["London, U.K., NW4 4BT"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-6107","authenticated-orcid":true,"given":"Ben","family":"Forbes","sequence":"additional","affiliation":[{"name":"King\u2019s College London , , ,","place":["London, U.K., SE1 9NH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3603-8839","authenticated-orcid":true,"given":"Chris","family":"Pepper","sequence":"additional","affiliation":[{"name":"Brighton and Sussex Medical School, University of Brighton and University of Sussex , ,","place":["Brighton, U.K., BN1 9PX"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-8648","authenticated-orcid":true,"given":"Khondaker Miraz","family":"Rahman","sequence":"additional","affiliation":[{"name":"King\u2019s College London , , ,","place":["London, U.K., SE1 9NH"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"3438","key":"2026073103234438000_cit1","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"issue":"14","key":"2026073103234438000_cit2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety\nof a specific inhibitor of the BCR-ABL tyrosine kinase in chronic\nmyeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5682","key":"2026073103234438000_cit3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding\nimatinib resistance with a novel ABL kinase\ninhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"6","key":"2026073103234438000_cit4","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression\nconfers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2026073103234438000_cit5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated\ndrug efflux\nis a resistance mechanism of chronic myelogenous leukemia cells to\ntreatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"issue":"10","key":"2026073103234438000_cit6","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly\nselective BCR-ABL tyrosine kinase inhibitor, is effective in patients\nwith Philadelphia chromosome-positive chronic myelogenous leukemia\nin chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2026073103234438000_cit7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction\nof the efflux transporters\nABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026073103234438000_cit8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/0470846356.ch7","article-title":"Reversal of multidrug\nresistance: lessons from clinical oncology","volume":"243","author":"Bates","year":"2002","journal-title":"Novartis Found. Symp."},{"issue":"13","key":"2026073103234438000_cit9","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.2174\/092986712800167392","article-title":"Three decades of\nP-gp inhibitors: skimming through several generations and scaffolds","volume":"19","author":"Palmeira","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"2026073103234438000_cit10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance\nin cancer: role\nof ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"2026073103234438000_cit11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting\nthe role of ABC transporters in multidrug-resistant\ncancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"2026073103234438000_cit12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters\nin cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"2026073103234438000_cit13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation\nof ABC transporter-mediated multidrug resistance in cancer: a review\nof the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"2026073103234438000_cit14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bcp.2016.01.014","article-title":"Interactions of human\nP-glycoprotein transport substrates\nand inhibitors at the drug binding domain: functional and molecular\ndocking analyses","volume":"104","author":"Kadioglu","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"19","key":"2026073103234438000_cit15","doi-asserted-by":"publisher","first-page":"17820","DOI":"10.1021\/acs.jmedchem.4c01852","article-title":"Computationally driven\ndiscovery of a BCR-ABL1 kinase inhibitor with activity in multidrug-resistant\nchronic myeloid leukemia","volume":"67","author":"Hill","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026073103234438000_cit16","doi-asserted-by":"publisher","first-page":"10470","DOI":"10.1038\/s41598-018-28531-6","article-title":"Mapping the dynamic functions and\nstructural features of AcrB efflux pump transporter using accelerated\nmolecular dynamics simulations","volume":"8","author":"Jamshidi","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"2026073103234438000_cit17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1021\/acs.jmedchem.1c01272","article-title":"Discovery\nand characterization of potent dual P-glycoprotein and CYP3A4 inhibitors:\ndesign, synthesis, cryo-EM analysis, and biological evaluations","volume":"65","author":"Urgaonkar","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026073103234438000_cit18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fmicb.2015.00302","article-title":"Substrate\nbinding accelerates the\nconformational transitions and substrate dissociation in multidrug\nefflux transporter AcrB","volume":"6","author":"Wang","year":"2015","journal-title":"Front. Microbiol."},{"issue":"1\u20132","key":"2026073103234438000_cit19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural\nbiology,\ndesign and clinical development of Bcr-Abl kinase inhibitors for the\ntreatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim.\nBiophys. Acta, Proteins Proteomics"},{"issue":"11","key":"2026073103234438000_cit20","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I:\nmechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"issue":"2","key":"2026073103234438000_cit21","first-page":"163","article-title":"Staphylococcal multidrug\nefflux protein QacA","volume":"3","author":"Brown","year":"2001","journal-title":"J. Mol. Microbiol. Biotechnol."},{"issue":"9","key":"2026073103234438000_cit22","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5155","article-title":"Mutational\nanalysis reveals the importance of residues of the access tunnel inhibitor\nsite to human P-glycoprotein (ABCB1)-mediated transport","volume":"33","author":"Salazar","year":"2024","journal-title":"Protein Sci."},{"issue":"7","key":"2026073103234438000_cit23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved\nsmall-molecule kinase\ninhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"2026073103234438000_cit24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s13059-014-0461-8","article-title":"Individualizing\nkinase-targeted cancer therapy: the\nparadigm of chronic myeloid leukemia","volume":"15","author":"Eiring","year":"2014","journal-title":"Genome\nBiol."},{"issue":"2","key":"2026073103234438000_cit25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/107327480301000207","article-title":"Overcoming multidrug\nresistance in cancer: an update\non the clinical strategy of inhibiting P-glycoprotein","volume":"10","author":"Thomas","year":"2003","journal-title":"Cancer Control"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c01596","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/21\/22619\/66300894\/acs.jmedchem.5c01596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/21\/22619\/66300894\/acs.jmedchem.5c01596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:23:48Z","timestamp":1785482628000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/21\/22619\/5235103\/Design-Synthesis-and-Biological-Evaluation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":25,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,10,25]]},"published-print":{"date-parts":[[2025,11,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01596","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]}}}